Document Detail


Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
MedLine Citation:
PMID:  17949554     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study autoantibody formation in patients with Behçet's disease (BD) who received long-term treatment with the anti-TNF monoclonal antibody infliximab. METHODS: Serial sera from infliximab-treated patients (5 mg/kg at weeks 0, 4, 8, and every 6-8 weeks thereafter) were tested for various autoantibodies, using commercially available methods, at baseline and at 6 months (n = 20), at 12 months (n = 16), and at 18 months post-baseline (n = 12). Thirty-five age- and sex-matched BD patients, not treated with infliximab, served as controls. RESULTS: Autoantibodies were rarely seen in controls, as well as in infliximab treated patients at baseline. Formation of antinuclear antibodies (ANA) at low titers was evident in 13/20 (65%) patients at 6 months post-baseline; one additional patient developed anti-beta2 glycoprotein-I IgM antibodies (anti-beta(2)GPI). Of the 13 ANA-positive sera, low titers-IgM of anti-dsDNA or anti-beta(2)GPI were detected in 7 (35%) and 6 (30%) patients, respectively. Additional measurements at 12 and 18 months showed that the persistence and/or increasing titers of these autoantibodies depended on continuation of treatment. Antibodies to extractable nuclear antigens (anti-RNP, anti-SS-A/Ro, anti-SS-B/La, anti-Sm), rheumatoid factors, anti-cyclic citrullinated peptide antibodies and antineutrophil cytoplasmic antibodies, were never detected. No antibody-related symptoms, lupus-like disease, or thrombosis were observed in any patient up to 18 months of follow-up. CONCLUSION: Early induction of ANA and specific autoantibodies is common in BD patients treated with infliximab, including low titers of non-pathogenic anti-dsDNA and anti-Beta<inf>2</inf>GPI antibodies. A possible clinical significance of these findings needs to be documented in further studies, including more patients and longer follow-up periods.
Authors:
A Elezoglou; N Kafasi; P H Kaklamanis; P G Theodossiadis; V Kapsimali; E Choremi; G Vaiopoulos; P P Sfikakis
Related Documents :
20298774 - Amino acid regions 357-368 and 418-427 of streptococcus pyogenes 60kda heat shock prote...
8126174 - Diagnostic value of anti-candida enolase antibodies.
20621654 - Anti-ku antibodies: clinical, genetic and diagnostic insights.
6094634 - Humoral immune responses to adenoviruses, herpes virus type 1, and candida albicans in ...
17009044 - Immunization of rhesus monkeys with a sialyltn-mab17-1a conjugate vaccine co-formulated...
21933194 - Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphyla...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  25     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2007 Jul-Aug
Date Detail:
Created Date:  2007-10-22     Completed Date:  2008-01-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  S65-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / adverse effects*
Autoantibodies / immunology*,  metabolism
Behcet Syndrome / drug therapy*
Case-Control Studies
Female
Humans
Immunologic Factors / adverse effects*
Male
Middle Aged
Prospective Studies
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Autoantibodies; 0/Immunologic Factors; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients.
Next Document:  Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vascul...